People who come off slimming jabs regain weight four times faster than dieters | BBC News

Key Concepts

• GLP-1 Receptor Agonists: Weight loss jabs like Monjaro and Wegovy, functioning by mimicking a natural hormone to regulate appetite and food intake.
• Weight Recidivism: The rapid regain of lost weight after discontinuing weight loss treatment.
• Clinical Trials & Meta-Analysis: Research methodology used to assess the efficacy and long-term effects of the medications.
• Long-Term Weight Management: The need for sustained strategies beyond medication to maintain weight loss.

Rapid Weight Regain Following Discontinuation of Weight Loss Jabs

Recent research published in the British Medical Journal highlights a significant concern regarding the long-term efficacy of weight loss medications like Monjaro and Wegovy (GLP-1 receptor agonists). The study indicates that individuals who cease using these jabs experience rapid weight regain, occurring approximately four times faster than those following traditional diet and exercise regimens.

Prevalence and Impact of Weight Loss Jabs in the UK

The use of these medications is becoming increasingly prevalent in the UK, with approximately 1 in 35 adults – equating to 1.66 million people – having utilized them in the past year. These drugs represent a shift in approaches to tackling obesity and dieting, offering a potentially more effective initial weight loss solution.

Patient Experience: Darren Ratcliffe’s Case

Darren Ratcliffe’s experience exemplifies this phenomenon. Weighing over 22 stone initially, he lost approximately four stone (56 lbs) over a six to eight-month period while on the medication, starting in February 2024. However, upon stopping the injections, he regained one stone (14 lbs) within a month. He anticipated some weight regain, but was surprised by the speed at which it occurred. This illustrates the challenge of maintaining weight loss after medication cessation.

Research Findings: Oxford University Meta-Analysis

Researchers at the University of Oxford conducted a meta-analysis of 37 previous clinical trials, encompassing data from 9,000 participants. The analysis revealed that patients on GLP-1 receptor agonists lost an average of 15 kg (2.5 stone or 33 lbs) during treatment. However, those who discontinued the medication regained an average of 10 kg (approximately 1.6 stone or 22 lbs) within the first year, with projections indicating a return to their original weight within 18 months. This rate of weight regain was four times faster than observed in individuals following conventional diet and exercise plans.

Expert Perspective: Not a "Silver Bullet"

The research underscores that these medications are not a permanent solution. As stated by researchers, “these drugs are really helpful in losing weight, but they’re not a silver bullet. They’re not a magic solution forever more.” The findings emphasize the necessity of integrating these medications into a comprehensive, long-term weight management strategy.

Long-Term Treatment Considerations & Lifestyle Changes

The study suggests that some patients may require ongoing treatment with weight loss jabs for life to maintain weight loss. Alternatively, or in conjunction, increased support for making lasting dietary and lifestyle modifications is crucial. The pharmaceutical companies involved, Eli Lilly and Novo Nordisk, acknowledge the potential for weight regain upon treatment cessation, drawing parallels to other chronic conditions like high blood pressure and diabetes which often necessitate continuous management.

Data & Statistics Recap

• UK Usage: 1.66 million adults used weight loss jabs in the last year.
• Average Weight Loss (During Treatment): 15 kg (2.5 stone / 33 lbs)
• Average Weight Regain (Within 1 Year of Stopping): 10 kg (1.6 stone / 22 lbs)
• Time to Return to Original Weight (Projected): 18 months
• Weight Regain Rate: Four times faster than with conventional diet and exercise.

Conclusion

The research clearly demonstrates the significant risk of rapid weight regain following the discontinuation of GLP-1 receptor agonists. While these medications are effective for initial weight loss, they are not a standalone solution. Successful long-term weight management necessitates a holistic approach, potentially including continued medication, alongside sustained lifestyle changes and ongoing support.